QIAGEN/$QGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About QIAGEN

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Ticker

$QGEN
Sector

Primary listing

NYSE

Employees

5,700

QIAGEN Metrics

BasicAdvanced
$10B
27.47
$1.69
0.64
$0.25
0.54%

Bulls say / Bears say

Net sales for Q2 2025 rose 7% year-over-year to $534 million, outpacing guidance of 5% constant exchange rate (CER) growth; adjusted diluted EPS reached $0.60.
Sales of diagnostic solutions grew 11% at CER, including 41% CER growth in QIAstat-Dx and 11% CER growth in QuantiFERON, highlighting strong portfolio momentum.
The adjusted operating income margin rose 1.5 percentage points to 29.9% of sales, reflecting improved efficiency and strict cost control.
Q2 2025 results were impacted by new U.S. and China import tariffs, which could lead to continued margin pressure if trade tensions remain.
Sales in Asia-Pacific fell 4% at constant exchange rates, with sharp declines in China and management not expecting a recovery before the back half of 2026, which dims regional growth outlook.
Management described the broader environment as complex and volatile, with academic customers and others remaining cautious on capital spending due to funding challenges, potentially limiting demand for life science products.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $QGEN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs